Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Sponsor: Revolution Medicines, Inc.
Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.
Official title: RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2025-12-15
Completion Date
2030-07-10
Last Updated
2026-04-06
Healthy Volunteers
No
Conditions
Interventions
daraxonrasib
oral tablets
Locations (15)
University of California, Los Angeles
Los Angeles, California, United States
University of California, San Francisco
San Francisco, California, United States
Hartford Healthcare
Hartford, Connecticut, United States
Community Health Network
Indianapolis, Indiana, United States
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Baltimore, Maryland, United States
Saint Luke's Cancer Institute
Kansas City, Missouri, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Taylor Cancer Research Center
Maumee, Ohio, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
University of Utah, Huntsman Cancer Institute
Salt Lake City, Utah, United States
Virginia Cancer Specialists
Fairfax, Virginia, United States
Pan American Oncology Trials, LLC
San Juan, Puerto Rico, Puerto Rico
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Medical Centre
Birmingham, United Kingdom
The Royal Marsden NHS Foundation Trust, Royal Marsden Hospital-London
London, United Kingdom
Imperial College Healthcare NHS Foundation Trust, Hammersmith Hospital
London, United Kingdom